Etoposide

目录号:S1225 别名: VP-16, VP-16213

Etoposide Chemical Structure

Molecular Weight(MW): 588.56

Etoposide是一种鬼臼毒素的半合成衍生物,通过抑制topoisomerase II 活性而抑制DNA合成。

规格 价格 库存 购买数量  
RMB 749.41 现货
RMB 575.72 现货
RMB 2290.17 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck该产品发表文献17篇:

客户使用该产品的8个实验数据:

  • ABT-199 synergizes strongly with lymphoma chemotherapy agents that affect MCL1 levels. Viability and CI vs Fa after 24-h exposure to etoposide alone or in combination with ABT-199 in Riva, U2932 and VavP-Bcl2/c-MYC murine tumor cells. Viability shown at 500 nM.

    Leukemia, 2015, 29: 1702–1712. Etoposide purchased from Selleck.

    a Immunofluorescence of HA–cGAS in transfected HCA2-TERT cells exposed to etoposide (100 μg/ml) for 4 h. b, Immunoblot of endogenous cGAS in the cytoplasmic and nuclear fractions of HCA2-TERT cells treated with etoposide for the indicated times

    Nature, 2018, 563(7729):131-136. Etoposide purchased from Selleck.

  • j, Immunoblot of cell lysates of PC-9 cells that stably express HA–cGAS, transfected with either shCtrl or shBLK after etoposide (100 μg ml−1) treatment for 4 h.

    Nature, 2018, 563(7729):131-136. Etoposide purchased from Selleck.

    Dox promotes formation of DNA DSBs in primary neurons. (A) Cortical neurons at 28–32 DIV were treated with a vehicle or with Dox (0.1 μ M) or with DNA damaging drug etoposide (5 μ M) overnight, fixed, and stained for a marker of DSBs phosphorylated histone H2A variant X, γ H2A.X (green), MAP2c (red), and with the nuclear Hoechst dye (blue), and imaged. The neuronal nucleus is enlarged on the Dox panel to illustrate the γ H2A.X puncta. Note the green nuclear staining in cells treated with Dox and etoposide. Also note the reduced dendritic arborization in neurons treated with Dox and etoposide. Scale bar is 20 μm.

    Sci Rep, 2016, 6:25705.. Etoposide purchased from Selleck.

  • Viability of U87 cells(C) assessed by the Alamar blue assay, 72 h after transfection with siRNA anti-survivin (siSURV) or with siMUT and/or cell incubation with the chemotherapeutical drugs etoposide (ETO) and Bliss interaction index (D) determined for the combined effects on cell viability of survivin silencing plus treatment with each drug. Cells were transfected, for 4 h, with (14Ser)2N5/siRNA/HL complexes and, after an additional period of 20 h, cells were incubated with 1.5 μM ETO (C) for 48 h. Results, representative of at least three independent experiments, are expressed as a percentage of the nontreated control cells. Combined treatment (dotted bar) was compared with the single drug treatment (gray bar) (**p < 0.01, ***p < 0.001) and the Bliss interaction index of each combined treatment was compared with the theoretical value expected for an additive effect (1.0) (#p < 0.05, ns, non-significant).

    Eur J Pharm Biopharm, 2016, 104:7-19.. Etoposide purchased from Selleck.

    Cellular biomarker responses in HT29 cells exposed to various cytotoxic chemotherapeutic agents in combination with the Chk1 inhibitor V158411. HT29 cells were exposed to the combination GI80 of gemcitabine (0.2 uM), camptothecin (0.44 uM), cisplatin (68 uM), oxaliplatin (131 uM), doxorubicin (1.2 uM) or etoposide (59 uM) for 18 hours followed by DMSO (-) or 400 nM V158411 (+) for a further 24 hours. Protein expression was characterized by immunoblotting.

    BMC Cancer 2014 14, 483. Etoposide purchased from Selleck.

  • (c) and (d) Effects of fractions C4 and C5 on topoisomerase II activity. Topoisomerase II activity was measured by plasmid DNA cleavage assay. DNA bands were visualized using UV light and the intensity of linear DNA band in each lane was measured using imageJ software. Lane 1: plasmid PBR322DNA. Lane 2: control, topoisomerase II + plasmid PBR322DNA. Lanes 3, 4, and 5: 40, 20, and 10 μg/mL fraction C4 + plasmid PBR322DNA, respectively. Lanes 6, 7, and 8: 40, 20, and 10 μg/mL fraction C5 + plasmid PBR322DNA, respectively. Lane 9: 100 μM etoposide + plasmid PBR322DNA. The data in different groups were expressed as the mean ± SD from 3 experiments. Statistical difference between groups was assessed by t-test using SPSS 20.0. ∗∗P < 0.01 versus the control group.

    Evid Based Complement Alternat Med, 2017, 2017:1456786. Etoposide purchased from Selleck.

    Effects of etoposide on the radiosensitivities of cholangiocarcinoma cell lines. The cell survival curves of (A) KKU-M055 and (B) KKU-M214 cells were obtained from clonogenic survival assays. The cells were treated with X-ray irradiation or etoposide (0.025 or 0.05 µg/ml) alone or pretreated with etoposide for 24 h prior to X-ray irradiation. Survival fractions were determined at day 10 following X-ray irradiation. The dose-response curves depict the mean ± standard deviation of survival fractions of three independent experiments. IR, irradiation.

    Oncol Lett, 2018, 15(3):3895-3903. Etoposide purchased from Selleck.

产品安全说明书

Topoisomerase抑制剂选择性比较

生物活性

产品描述 Etoposide是一种鬼臼毒素的半合成衍生物,通过抑制topoisomerase II 活性而抑制DNA合成。
靶点
Topo II [2]
(Cell-free assay)
体外研究

Etoposide通过与Topoisomerase II 和 DNA形成复合物而抑制DNA合成,诱导双链DNA断裂,且阻碍通过 Topoisomerase II结合修复。DNA持续断裂阻碍进入细胞有丝分裂期,进而导致细胞死亡。Etoposide主要作用于细胞周期的G2期和S期。[1] Etoposide 抑制鼠类血管肉瘤细胞系 (ISOS-1) 生长,IC50 为0.25 μg/mL。Etoposide 抑制人类白血病成淋巴细胞系CCRF-CEM的四倍体克隆,IC50为0.6 μM。[3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Kelly MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIfrWYFKSzVyPUCuNVLjiIoEsfMAjVAvODFizszN NFrUOmkzPTl4MEK4Ni=>
KellyCis83 M4q3OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{njZ2lEPTB;MD6xOwKBkcLz4pEJNE4xOiEQvF2= M1ewbVI2QTZyMkiy
SK-N-AS M2rZT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWS3Sok1UUN3ME2wMlI16oDLwsJihKkxNjB|IN88US=> MmC4NlU6PjB{OEK=
SK-N-ASCis24 NWG3TIF3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFzI[odKSzVyPUCuOVfjiIoEsfMAjVAvOTFizszN Mkf1NlU6PjB{OEK=
U87 M3;0NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIfIdW4xNTVyIN88US=> NX7reo5zPDhiaB?= Mn[z[IVkemWjc3XzJINmdGxidnnhZoltcXS7IIfobYNpKGOjbjDi[UBmdmijbnPl[EBjgSC|aXzpZolvcW5? M3jOT|I2PzVyMkez
HCT116 MnPiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYqwMlUuOi53IN88US=> NVnJUlFMPDkEoHlCpC=> NYjnVoN[UUN3ME2xMlc{yqEEsdMgNE4zOcLizszN NXXBWJdwOjV5NE[3OlM>
HT-29 NULCWHVzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXmwMlUuOi53IN88US=> MkDUOFjDqGkEoB?= NHTzW5lKSzVyPUeuNuKhyrIEoEGuNFTDqM7:TR?= M13LWFI2PzR4N{[z
Caco2 NEPTW3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWjnOZhROC53LUKuOUDPxE1? NI[yd2Q1QMLiaNMg NHz5WFRKSzVyPUeuNlbDqMLzwrCxMlY5yqEQvF2= NFrDc20zPTd2Nke2Ny=>
COLO 205 NYLhbpZVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVGwMlUuOi53IN88US=> NEH1UHE1QMLiaNMg MUnJR|UxRTFwNkJCpOKyyqByLkCyxsDPxE1? MUOyOVc1Pjd4Mx?=
SW480 NIeyd4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3jtOVAvPS1{LkWg{txO MkLWOFjDqGkEoB?= NIW2V3ZKSzVyPUSuPVLDqMLzwrCwMlM{yqEQvF2= NWDNZYZROjV5NE[3OlM>
HEK293T MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml\vNU02KM7:TR?= NH7SXVU1QMLiaNMg NGLZ[lFKSzVyPUKuOFLDqMLzwrCwMlA2yqEQvF2= M2SyUlI2PzR4N{[z
Hep3B  MUHGeY5kfGmxbjDBd5NigQ>? MljpNVAh|ryP M1S1RVQ5yqCqwrC= NH:zbphz\WS3Y3XzJJRp\SCnbnjhcoNqdmdiZX\m[YN1KG:oIFLNVE03 NFXUXW0zPTZ|M{W2OC=>
Hep3B  MUXGeY5kfGmxbjDBd5NigQ>? NFLnPGYxNjFvMUCg{txO MXKyOEBp Ml;ad5VxeHKnc4Pld{B1cGViZYjwdoV{e2mxbjDv[kBp\XClaXTpckBuWk6D MnrvNlU3OzN3NkS=
HEK293 MnzwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NW\ZRVVXUUN3ME23MlE1yqEEsdMgNE4{PsLizszN NVnKTFRqOjV4MEOxNlI>
DU145 NVezWm5sT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MojBTWM2OD1{LkK4xsDDucLiMD6wOOKh|ryP M4XXdFI2PjB|MUKy
HCT15 NFXXNY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUPJR|UxRTBwOEJCpOKyyqByLkCxxsDPxE1? NIfxU5UzPTZyM{GyNi=>
T47D M{fMb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUGydW1OUUN3ME2zMlE5yqEEsdMgNE4yOcLizszN NWfXNnZrOjV4MEOxNlI>
SMMC-7721 MVrGeY5kfGmxbjDBd5NigQ>? M3jWOlQxKM7:TR?= NEKzflk1QCCq MXnEUXNQ MVvpcoR2[2W|IN8zTFJCYCCob3PpJIZwem2jdHnvci=> MXyyOVU1PDN4MR?=
MDA-MB-231 NHv6dnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVTHWoE6PzMEoHi= MoP1TWM2OD1{MT6yxsDDucLiND6yxsDPxE1? NI\oOJgzPTR6NkKxPS=>
MCF-7 MkjlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYC3NuKhcA>? MnjuTWM2OD1zMD65xsDDucLiMj6xxsDPxE1? MU[yOVQ5PjJzOR?=
Jurkat NETCS3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUPFZlEzPzMEoHi= M2LPO2lEPTB;MT6yxsDDucLiMT61xsDPxE1? M2X5UVI2PDh4MkG5
HeLa NFW3UIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYq3NuKhcA>? NEjjdHFKSzVyPUOuPeKhyrIEoEKuN:Kh|ryP M1\0d|I2PDh4MkG5
MCF7  NYG2TWhYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NY\EPGFpPS1zMECg{txO M{LaWVch\A>? MlLobY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> MWSyOVQ4OjZzOR?=
K562 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXu3NuKhcA>? MWfJR|UxRTBwMkpCpO69VQ>? NFXpT5ozPTJ6Mk[1Ny=>
K/VP.5 Mn\LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYnTdlRqPzMEoHi= NYXqWmRxUUN3ME20MlnDqM7:TR?= MW[yOVI5OjZ3Mx?=
SH-EP  NWjUdZdUTnWwY4Tpc44hSXO|YYm= M4n5RVIxyqEQvHevcYw> M1fS[FI1yqCq MlzybY5kemWjc3XzJJRp\SCneIDy[ZN{cW:wIH;mJIVv\G:pZX7veZMhTEWSUB?= Moe0NlUzPjF7OEG=
SCC25 NXGxNpNNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1rDZ|I1yqCq NHrMNJlKSzVyPUSzMlPDqMLzwrCxMlEzyqEQvF2= NES3SpgzPTJ{MEeyPS=>
CAL27 M2XJTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH33c2gzPMLiaB?= Mn;UTWM2OD13Mj6xxsDDucLiMT6wPeKh|ryP NUXXRYNIOjV{MkC3Nlk>
FaDu NV[5NoQzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkLlNlTDqGh? M3np[GlEPTB;MkWuPFnDqMLzwrCxMlE{yqEQvF2= MViyOVIzODd{OR?=
SCC25 MmTGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGjFOnk1QMLiaB?= M3zwemlEPTB;MkCuPFbDqMLzwrCxMlA4yqEQvF2= Ml3pNlUzOjB5Mkm=
CAL27 NEDtOY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWq0POKhcA>? MlPxTWM2OD1zOD6yOOKhyrIEoEGuNVXDqM7:TR?= MnnENlUzOjB5Mkm=
FaDu MnfZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHHzdFI1QMLiaB?= Mn\KTWM2OD14LkSzxsDDucLiMT6xN:Kh|ryP MnrkNlUzOjB5Mkm=
SCC25 M2XNeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF\MfnU4OsLiaB?= MVjJR|UxRThwNEJCpOKyyqBzLkGxxsDPxE1? MWeyOVIzODd{OR?=
CAL27 M37xPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVHzSWtsPzMEoHi= MmTxTWM2OD12LkK3xsDDucLiMT6xOOKh|ryP NYW0XHU4OjV{MkC3Nlk>
FaDu MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHL4W4Y4OsLiaB?= NVHmPJFxUUN3ME21MlAzyqEEsdMgNU4yPcLizszN M2ezO|I2OjJyN{K5
MCF-7 NHXKdZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M17sSFQ5yqCqwrC= NVjlZ4RpTE2VTx?= Mnn2TWM2OD15LkNCpOKyyqByLklCpO69VQ>? M3fEbFI2OjF4M{e4
T-47D MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV65OmNnPDkEoHlCpC=> MX7EUXNQ MWfJR|UxRTdwN9MgxtHDqDBwN9Mg{txO Mlf5NlUzOTZ|N{i=
MDA-MB-231 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3fPSFQ5yqCqwrC= MXrEUXNQ M3nkbWlEPTB;MUKuPOKhyrIEoEGuNOKh|ryP MmDuNlUzOTZ|N{i=
DU145 NEXQeYZCeG:ydH;zbZMhSXO|YYm= Ml\0NVAuOTByIN88US=> NUHQd5I5QCCq NVnUWHRQTE2VTx?= MVXpcoR2[2W|IHPlcIwh\GWjdHigd4lodmmoaXPhcpRtgSCrbjDhJJZmenlibH;3JINwdmOnboTyZZRqd25? M1nlUVI2OTR7Nkix
DU145 stem-like NFrLSmRCeG:ydH;zbZMhSXO|YYm= MlvLNVAuOTByIN88US=> MlvCPEBp MlfBSG1UVw>? NViwW41TcW6mdXPld{Bk\WyuIHTlZZRpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz MU[yOVE1QTZ6MR?=
DU145 NXi0Z3ZmTnWwY4Tpc44hSXO|YYm= MoTBNVAuOTByIN88US=> MY[yJIg> M{\2fmROW09? NXrZdWc2cW6lcnXhd4V{KHSqZTDwR2hMOSCneIDy[ZN{cW:wIHHu[EBl\WO{ZXHz[ZMhfGinIIDDTGsyKGW6cILld5Nqd25iaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? Mke2NlUyPDl4OEG=
DU145 stem-like MVTGeY5kfGmxbjDBd5NigQ>? MX[xNE0yODBizszN MkP3NkBp MlvMSG1UVw>? NW\OWZRKcW6lcnXhd4V{KHSqZTDwR2hMOSCneIDy[ZN{cW:wIHHu[EBl\WO{ZXHz[ZMhfGinIIDDTGsyKGW6cILld5Nqd25iaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NXnjd4ZZOjVzNEm2PFE>
UW228-3 NUXXfXlCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXLVRYdWOC5yMT2zNFAh|ryP NIO5TmM1QCCq M4DRWWROW09? NHL0XHBKSzVyPUCuPVnDqM7:TR?= Mn76NlUyOTlzOEW=
NSCs Mki5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWqwMlAyNTNyMDFOwG0> M164PVQ5KGh? NVvkR49mTE2VTx?= NHfHR3JKSzVyPUCuN{0{yqEQvF2= NFvnV4IzPTFzOUG4OS=>
MKL-1  Mn23SpVv[3Srb36gRZN{[Xl? NUf4WodSOTBvMUCwNEBvVQ>? NEjiemE1KGR? NXvmW21icW6mdXPld{B1cGViaX7keYN1cW:wIH;mJG1JSy2LIHX4dJJme3Orb36= M4\TSlI2OTF4N{W0
MCF7 EV NGT2d|RHfW6ldHnvckBCe3OjeR?= NE\U[5IyOC1zMECg{txO NILtZYYz6oDLaB?= NEPjS5lqdmS3Y3XzJJBzd2S3Y4Tpc44hd2cEoN8zTFJCYA>? NXXM[2hKOjVyOEiyNFM>
MCF 7BMI1 NInw[5VHfW6ldHnvckBCe3OjeR?= NULpN2J[OTBvMUCwJO69VQ>? NFqyfI8z6oDLaB?= NHH1[FJqdmS3Y3XzJJBzd2S3Y4Tpc44hd2cEoN8zTFJCYA>? NWjifYh4OjVyOEiyNFM>
MCF7 EV M33JfGZ2dmO2aX;uJGF{e2G7 NF;U[28yOC1zMECg{txO MmrLNwKBkWh? M2q4dmVVV1BiaX7keYNmeyCDVF2gZYN1cX[jdHnvci=> M2fHNVI2ODh6MkCz
MCF7 BMI1 MXrGeY5kfGmxbjDBd5NigQ>? M1LZW|ExNTFyMDFOwG0> NUP6PVBDOuLCiXi= Ml[2SXRQWCCrbnT1Z4V{KEGWTTDhZ5RqfmG2aX;u MYKyOVA5QDJyMx?=
HepG2 M1WwOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml3YSG1UV8Li NHvYXWxKSzVyPUOwMlE3yqEEsdMgNE42OMLizszN Mmf6NlUxPzh|MUG=
MOLT-3 M335bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NE\nV4tFVVORwrC= Ml;uTWM2OD1yLkC1NeKhyrIEoECuNFAzyqEQvF2= NYf4W|VVOjVyN{izNVE>
HT1080 M1zrW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUSxMVExOCEQvF2= NGTvZYo1NzJ2L{S4JIg> NGXYXWFFVVORwrC= NEXBcoRqdmS3Y3XzJINmdGxiZHXheIghe2mpbnnmbYNidnSueTDpckBiKH[ncomgcI94KGOxbnPlcpRz[XSrb36= M{HVRlI2ODd6ME[0
HT1080 NGPGfFNHfW6ldHnvckBCe3OjeR?= MWewMlAxODFvMUCwJO69VQ>? MlfQNU0zPCCq NEfmZYtFVVORwrC= NETEc|NqdmS3Y3XzJJAueDV|KIPldlE2MSCrbjDic5RpKHSrbXWtJIFv\CClb37j[Y51emG2aX;uMYRmeGWwZHXueEBu[W6wZYK= M3n6VlI2ODd6ME[0
HT1080 NIfEc4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHLFcHIxNjByMEGtNVAxKM7:TR?= M37WelI1KGh? MmriSG1UV8Li M4XIVoNifXOnczDhckBqdmO{ZXHz[UBqdiC2aHWgcpVu[mW{IH;mJINmdGy|IHnuJGczN01uIIfobYxmKGSnY4LlZZNqdmdiUzDhcoQhTzFicHjhd4Uh[2WubIO= M3nzUVI2ODd6ME[0
HD-MY-Z MonsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1fKPVI1NzR6L{eyJIg> M{jkR2lEPTExvK6xNFAh|ryP NUDwT4FROjVyNEiyN|Y>
DOHH-2 NVrBcI1ET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIfmflMzPCCq M4XjSWlEPTExvK6xNFAh|ryP M{G5RlI2ODR6MkO2
DOHH-2 Mne0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYX4c|JIPDhiaB?= Mn3GTWM2OD1zOT65xsDPxE1? M3fvcVI2ODR6MkO2
DOHH-2 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV23NkBp NX7YbGFvUUN3ME21xsDPxE1? MorBNlUxPDh{M{[=
REH NFLUVlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXHMPFJ2OjRiaB?= M{TQVmlEPTB;MD6wNlfDqM7:TR?= MlHhNlUxPDh{M{[=
REH M3jBdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFXmUlk1QCCq Mof0TWM2OD1yLkCxOOKh|ryP NIPBfnYzPTB2OEKzOi=>
REH NWXse404T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYG3NkBp Mkj2TWM2OD1yLkCxOeKh|ryP NVnzXmxuOjVyNEiyN|Y>
HH NET5WZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoT5NlQhcA>? M1LEeWlEPTB;MUC0MlfDqM7:TR?= M1T1SFI2ODR6MkO2
HH M1zqUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGHvUZA1QCCq MmW1TWM2OD12OD62xsDPxE1? NGnKR3kzPTB2OEKzOi=>
HH MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVO3NkBp NG\XT25KSzVyPUG0MlfDqM7:TR?= MVuyOVA1QDJ|Nh?=
HuT-78 NILxNYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmrpNlQhcA>? MXrJR|UxRTlwM9Mg{txO MUCyOVA1QDJ|Nh?=
HuT-78 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmjyOFghcA>? M3joXWlEPTB;ND6zxsDPxE1? NYLX[YNQOjVyNEiyN|Y>
HuT-78 MmTPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3XjUVczKGh? NXLFcFF1UUN3ME20MlLDqM7:TR?= NHm4dXIzPTB2OEKzOi=>
OPM-2 M{LSc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1z1V|I1KGh? MYrJR|UxRTJ2LkJCpO69VQ>? MVSyOVA1QDJ|Nh?=
OPM-2 Mkj5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnnjOFghcA>? MoL0TWM2OD12wrFOwG0> NHm1NlMzPTB2OEKzOi=>
OPM-2 NWDKcZpST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVK3NkBp MljjTWM2OD1zLkRCpO69VQ>? MoSyNlUxPDh{M{[=
RPMI-8226 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWmyOEBp NEf1c5BKSzVyPUGwOk43yqEQvF2= MoCxNlUxPDh{M{[=
RPMI-8226 MkflS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYi0PEBp NGLje5pKSzVyPUmxMlHDqM7:TR?= MlOwNlUxPDh{M{[=
RPMI-8226 NW\nXJp6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUm3NkBp NIPaUWdKSzVyPUG0MlnDqM7:TR?= M2DtWlI2ODR6MkO2
U-266 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoHJNlQhcA>? NGfwWHFKSzVyPUi2MlLDqM7:TR?= M{T5UFI2ODR6MkO2
U-266 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnvrOFghcA>? MUfJR|UxRTZ6LkVCpO69VQ>? MVmyOVA1QDJ|Nh?=
U-266 NGLIeHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFnYcJA4OiCq M2W0dGlEPTB;MkeuOOKh|ryP Mn3vNlUxPDh{M{[=
Kelly MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVTKXoRuOC1zMDFOwG0> M{H4RlczyqCq MUPJR|UxRTFwNUG4xsDPxE1? M{fNfFI2ODB6OUCw
SH-SY5Y  MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlnuNE0yOCEQvF2= NWHxT5h[PzMEoHi= MVXJR|UxRTBwN{W0xsDPxE4EoB?= NXrNWo5pOjVyMEi5NFA>
SK-N-AS MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEnpWm0xNTFyIN88US=> MVy3NuKhcA>? MomzTWM2OD1zLkexNuKh|ryPwrC= MUmyOVAxQDlyMB?=
SK-N-DZ NH\VZpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEPhPIoxNTFyIN88US=> M370NVczyqCq M2TrNWlEPTB;NT60PFXDqM7:TR?= NYnMcVA1OjVyMEi5NFA>
HepG2 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUjxNnA3PDkEoHi= MYXEUXNQyqB? MkHYTWM2OD1zMz62OeKhyrIEoECuPVLDqM7:TR?= MnviNlQ6QTZzM{[=
A549 NGXjO5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmjWOFjDqGh? M1u4UGROW00EoB?= MVrJR|UxRTJ2MT65xsDDucLiM{GuNlPDqM7:TR?= M4rI[|I1QTl4MUO2
MCF7 NVrOZ3d6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NInZW2M1QMLiaB?= M2\iT2ROW00EoB?= NX3wTYVKUUN3ME24NU4xQcLiwsJCpFE1NjJzwrFOwG0> MmrWNlQ6QTZzM{[=
HL-60  NULtNnJ1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHXOSmw4OsLiaB?= M{nIOWlEPTB;MD6xNwKBjc7:TR?= MlrDNlQ6QTNyMUS=
HL-60[R] NGX1TZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoHoO|LDqGh? NEHPVYdKSzVyPUOuNVLjiIYQvF2= MnLCNlQ6QTNyMUS=
MIAPACA M3\rN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlfES2k2OD1zLkOgxtEhOC5yMzFOwG0> MV6yOFk2Ozh{MR?=
MCF-7 MkPuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVPHTVUxRTBwMkWgxtEhOC5zIN88US=> NVq0V4V3OjR7NUO4NlE>
HeLa M1vSdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWXJc3N5T0l3ME2wMlY1KMLzIECuOEDPxE1? M2TDdlI1QTV|OEKx
MO59K  MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXG3JIQ> NYLkXlVDUUN3ME2wMlE46oDHzszN M{SxOFI1QTV|NU[x
MO59J NHm0eGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoLDO{Bl M2LSWmlEPTB;MD6x5qCG|ryP M1jxOVI1QTV|NU[x
ME 180 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnO2OFjDqGkEoB?= NX3iOVBiUUN3ME24MlnDqMLzwrCwMlPjiIYQvF2= M2\ibFI1QTV|MEK3
MCF-7 NEDKXFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWf0Z2txPDkEoHlCpC=> MUDJR|UxRTJ|LkmgxtEhOC5|4pEF{txO MVmyOFk2OzB{Nx?=
HeLa NWO1VlhuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1PHWlQ5yqCqwrC= Mm\2TWM2OD12LkexJOKyKDFwNPMAie69VQ>? M{PwN|I1QTV|MEK3
MDA-MB-453 MlXrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3vQTFQ5yqCqwrC= MmL4TWM2OD1zMj61JOKyKDBwOEZihKXPxE1? NVHlS4t{OjR7NUOwNlc>
MDA-MB-231 M1jrU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVe0POKhcMLi MmLRTWM2OD1{ND6yNkDDuSB{Lkm05qCG|ryP MoGzNlQ6PTNyMke=
PC-3 M3fIdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NU\ONmptPDkEoHlCpC=> NVr3SVBxUUN3ME2xOE41KMLzIEOuNlPjiIYQvF2= MlvYNlQ6PTNyMke=
HT-29 NGnNOIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXe0POKhcMLi NVPGdnlVUUN3ME2yNU41PSEEsTCzMlg46oDHzszN NEDpe3QzPDl3M{CyOy=>
BGC-823 M2DCc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXX2e5dzPDkEoHlCpC=> NXjzdWlWUUN3ME20N{44PCEEsTC1MlE{6oDHzszN M3;4fVI1Pzl|OEe3
HeLa NWTCeJFmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWe0POKhcMLi Moe2TWM2OD1{MEmuPVAhyrFiMUOuOFIh6oDHzszN MYKyOFc6Ozh5Nx?=
A549 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkPWOFjDqGkEoB?= NVLSZ3hmUUN3ME2xN|kvPTRiwsGgO{4xPeLChd88US=> NEPoWXgzPDd7M{i3Oy=>
HK-2 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGntbZE1QMLiaNMg MXHJR|UxRTlwMUegxtEhOS53OPMAie69VQ>? MljCNlQ4QTN6N{e=

... Click to View More Cell Line Experimental Data

体内研究 Etoposide 作用于Lewis 肺癌,诱导肿瘤免疫。Etoposide按50 mg/kg剂量单独腹腔注射给药注射了Lewis肺癌细胞 (3LL)的C57B1/6小鼠,诱导60%存活。[4]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验:[5]
+ 展开

Topoisomerase II 活性测定:

制备核提取物,进行核分离。在Topoisomerase II去连环过程中获得去连环百分数而计算Topoisomerase II的活性。氚标记的kinoplast DNA (KDNA 0.22 μg)作为底物。Etoposide 与 Topoisomerase II在37°C 下温育30分钟,然后加入1%十二烷基硫酸钠(SDS)和蛋白酶K(100 μg/mL)终止。通过Etoposide获得去连环百分数和 Topoisomerase II 抑制情况。
细胞实验:[5]
+ 展开
  • Cell lines: 人类胶质瘤细胞系CL5
  • Concentrations: 80 μg/mL
  • Incubation Time: 1 小时
  • Method: Etoposide处理后,使用含有0.03%胰蛋白酶和0.27 mM乙二胺四乙酸(EDTA)的磷酸盐缓冲液(PBS)将细胞从培养皿中移去,然后在培养皿中稀释到适当数目,获得20到200个菌落。12天后,使用甲醇-乙酸固定培养基,使用结晶紫进行染色,并计数超过50个细胞的菌落。
    (Only for Reference)
动物实验:[2]
+ 展开
  • Animal Models: 携带血管肉瘤移植瘤ISOS-1 的小鼠
  • Formulation: 生理盐水
  • Dosages: 10 mg/kg
  • Administration: 从实验第7天开始,每天腹腔注射,持续5天
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 100 mg/mL (169.9 mM)
Water Insoluble
Ethanol Insoluble
体内 从左到右依次将纯溶剂加入产品,现配现用(数据来自Selleck实验检测而非文献):
5% DMSO+30% PEG 300+H2O
15mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 588.56
化学式

C29H32O13

CAS号 33419-42-0
稳定性 powder
in solvent
别名 VP-16, VP-16213

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03349346 Recruiting Diffuse Large B-Cell Lymphoma|Mediastinal B-cell Lymphoma Gilead Sciences June 2019 Phase 1
NCT03669783 Not yet recruiting Childhood Renal Tumor Assistance Publique Hopitaux De Marseille January 1 2019 Phase 3
NCT03742115 Not yet recruiting Hemophagocytic Lymphohistiocytosis Beijing Friendship Hospital December 1 2018 Phase 3
NCT03711305 Not yet recruiting Extensive-stage Small Cell Lung Cancer Jiangsu HengRui Medicine Co. Ltd. December 2018 Phase 3
NCT03579927 Not yet recruiting CD19 Positive|Mantle Cell Lymphoma|Recurrent Diffuse Large B-Cell Lymphoma|Recurrent Follicular Lymphoma|Refractory B-Cell Non-Hodgkin Lymphoma|Refractory Diffuse Large B-Cell Lymphoma|Refractory Follicular Lymphoma M.D. Anderson Cancer Center|National Cancer Institute (NCI) December 2018 Phase 1|Phase 2
NCT03531281 Not yet recruiting Hematopoietic and Lymphoid Cell Neoplasm|Hematopoietic Cell Transplantation Recipient City of Hope Medical Center|National Cancer Institute (NCI) December 30 2018 Phase 1

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

常见问题及建议解决方法

  • 问题 1:

    Regarding the Etoposide S1225, do you have any data of the inhibition sepcificity of this product? It will inhibit other enzymes other than TOP2A?

  • 回答:

    According to the available published data, the inhibition of Etoposide is specific to TOP2A. But there're also two papers showing that Etoposide could inhibit the p34cdc2 Kinase Activity: 1. http://cancerres.aacrjournals.org/content/52/7/1817.short ; 2. http://cancerres.aacrjournals.org/content/50/12/3761.short.

Topoisomerase Signaling Pathway Map

相关Topoisomerase产品

Tags: 购买Etoposide | Etoposide供应商 | 采购Etoposide | Etoposide价格 | Etoposide生产 | 订购Etoposide | Etoposide代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID